z-logo
open-access-imgOpen Access
Washed microbiota transplantation stopped the deterioration of amyotrophic lateral sclerosis: The first case report and narrative review
Author(s) -
Gaochen Lu,
Qiuyuan Wen,
Bota Cui,
Qianqian Li,
Faming Zhang
Publication year - 2023
Publication title -
journal of biomedical research/journal of biomedical research
Language(s) - English
Resource type - Journals
eISSN - 2352-4685
pISSN - 1674-8301
DOI - 10.7555/jbr.36.20220088
Subject(s) - amyotrophic lateral sclerosis , medicine , neurodegeneration , gut flora , disease , transplantation , fecal bacteriotherapy , antibiotics , immunology , biology , clostridium difficile , microbiology and biotechnology
Amyotrophic lateral sclerosis (ALS) is known as a progressive paralysis disorder characterized by degeneration of upper and lower motor neurons, and has an average survival time of three to five years. Growing evidence has suggested a bidirectional link between gut microbiota and neurodegeneration. Here we aimed to report one female case with ALS, who benefited from washed microbiota transplantation (WMT), an improved fecal microbiota transplantation (FMT), through a transendoscopic enteral tube during a 12-month follow-up. Notedly, the accidental scalp trauma the patient suffered later was treated with prescribed antibiotics that caused ALS deterioration. The subsequent rescue WMTs successfully stopped the progression of the disease with a quick improvement. The plateaus and reversals occurred during the whole course of WMT. The stool and blood samples from the first WMT to the last were collected for dynamic microbial and metabolomic analysis. We observed the microbial and metabolomic changing trend consistent with the disease status. This case report for the first time shows the direct clinical evidence on using WMT for treating ALS, indicating that WMT may be the novel treatment strategy for controlling this so-called incurable disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here